Program Description: 


ISTH Academy Webinar: Acute Thrombotic Microangiopathies

  • TTP – Spero Cataland (USA)

The underlying pathophysiology of acquired TTP will be briefly summarized to set the stage for the discussion on novel therapeutic approaches to the treatment of acquired TTP.  We will also discuss recent research describing the development of long-term complications in patients with a prior history including neurocognitive and neuropsychologic complications. 

  • aHUS – genomics of diagnosis & management  – Piers Blombery (Australia)

The genetic lesions that are known to cause atypical haemolytic uremic syndrome (aHUS) and various laboratory methods used to detect these changes. The implications of the identification of genetic lesions in diagnosis and management of patients with aHUS.



Accreditation Statement


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
More information and online registration: 

Supported by and unrestricted educational grant from Instrumentation Laboratory

Target audience: 

Hematologists and other physicians that are involved in the initial and long-term care of patients diagnosed with acquired TTP. Consultant and training haematologists, nephrologist and molecular pathologists.


Learning objectives: 

At the end of this Webinar, the participants will be able to:

  • To be able to understand the pathophysiology of acquired TTP and its relevance to treatment
  • To learn about novel, more targeted approaches to therapy of acquired TTP
  • To be able to recognize the presence of long term complications from a prior diagnosis of TTP including neurocognitive changes, headaches, mood disorders, and vascular complications
  • To better understand the appropriate long-term follow-up for TTP patients to be able to diagnose these long-term complications and assess the risk for relapse
  • Understand the current diagnostic definitions and classification of aHUS and its limitations
  • Understand the diversity of genetic lesions known to result in aHUS
  • Understand the basic laboratory methodologies used to detect these changes and their strengths and limitations
  • Understand the role detection of genetic lesions has in the diagnosis and management of aHUS
Faculty & credentials: 
Planning Committee:
Geoffrey Barnes, MD
Chris Ward, PhD
Stephen Watson, PhD
Yukio Ozaki
Spero Cataland
Piers Blombery
Chris Ward, PhD

All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  





Geoffrey Barnes, MDPortolaConsulting
 Blue Cross Blue Shield of MichiganResearch
Chris Ward, PhDBayerSpeaker
 Boehringer-IngelheimSpeaker, Advisory Board
 BMS/PfizerSpeaker, Advisory Board
 Sanofi-Aventis, AlexionSpeaker, Advisory Board
Yukio OzakiThe Sysmex CorporationAdvisory Board
Spero CatalandAblynxConsultant

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved






Lacey Schmeidler, MA
Phone number: 
+1 (919) 929-3807
Session date: 
12/14/2016 - 3:00pm to 4:00pm CST
ISTH Webinar Library Once a Month
Carrboro, NC 27510
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.